SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

Kite to Collaborate with Epic Bio to Develop New Therapies for Cancer

Here is a brief preview of this blast: On Tuesday, October 31, Gilead (Kite) announced a research collaboration and license agreement with Epicrispr Biotechnologies (Epic Bio) for the use of Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies (press release). Below, Celltelligence provides insights on how Gilead could leverage Epic Bio’s platform to develop better cell therapies for hematological diseases.